View text source at Wikipedia

Patients for Affordable Drugs Now

Patients For Affordable Drugs Now is a patient advocacy and lobbying organisation based in Washington, D.C., which focuses on policies to lower drug prices in the United States. It was founded by David Mitchell (who suffers from multiple myeloma), and has Merith Basey as its Executive Director since 2022.

It is financed by the Action Now Initiative (ANI) which is funded by the Laura and John Arnold Foundation.[1] It is bipartisan and does not accept funding from any organizations that profit from development or distribution of prescription drugs.[2]

Patients For Affordable Drugs Now has a separate political action arm called Patients for Affordable Drugs Action.[3] It spent about $10 million to highlight drug prices as an issue in the 2018 United States elections.[4]

In March 2019 Mitchell welcomed the suggestion that drug companies should be made to disclose the prices of their products in television commercials but said “We have not seen any evidence that it will lower drug prices."[5]

When Eli Lilly and Company announced a halving of the price of insulin lispro Wakana denounced the move as a "token PR play".[6]

It supports the proposal for a Prescription Drug Affordability Board as is being considered in Maryland[7] and similar proposals made in Washington.[8]

In 2022 it pointed out that the price of Humalog, Eli Lilly's insulin had increased from $20 in 1996 to $275.[9]

References

[edit]
  1. ^ "Who's P4ADNOW?". Patients For Affordable Drugs Now. Retrieved 2019-04-24.
  2. ^ Lieberman, Trudy. "Maybe the U.S. is finally serious about lowering drug prices". Post-Tribune. Retrieved 2019-04-24.
  3. ^ McCarthy, Tom (2018-10-28). "'Supporting greed over needs': the group taking on big pharma in the midterms". The Guardian. ISSN 0261-3077. Retrieved 2019-04-24.
  4. ^ "Why is this drug pricing PAC spending millions on long-shot races?". STAT. 2018-10-05. Retrieved 2019-04-24.
  5. ^ "Drug Prices on TV? They May Be Coming". New York Times. 23 March 2019. Retrieved 15 April 2019.
  6. ^ "Drug company announces new version of insulin at half the price". The Hill. 3 April 2019. Retrieved 15 April 2019.
  7. ^ "Maryland drug affordability board 'can be national model', claims group". The PharmaLetter. 29 March 2019. Retrieved 15 April 2019.
  8. ^ "Legal News: New campaign supports drug pricing measures". Tacoma Weekly. 5 April 2019. Retrieved 15 April 2019.
  9. ^ "A Twitter meltdown sheds light on the murky economics of insulin". Marketplace. 14 November 2022. Retrieved 19 November 2022.
[edit]